MANKIND.NS Cash Flow
Mankind Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:37
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹18.13 Bn | ₹21.52 Bn | ₹24.13 Bn | ₹31.21 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-10.54 Bn | ₹-20.82 Bn | ₹-126.83 Bn | ₹-1.96 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-7.40 Bn | ₹0.05 Bn | ₹102.90 Bn | ₹-29.53 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.02 Bn | ₹0.01 Bn | ₹0.01 Bn | ₹0.16 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹0.22 Bn | ₹0.77 Bn | ₹0.22 Bn | ₹-0.12 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹2.83 Bn | ₹3.05 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from MANKIND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).